This Article Full Text Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kiely, J.-M. Articles by Gimbrone, M. A. Search for Related Content PubMed PubMed Citation Articles by Kiely, J.-M. Articles by Gimbrone, M. A., Jr

(Arteriosclerosis, Thrombosis, and Vascular Biology. 1995;15:1211-1218.)
© 1995 American Heart Association, Inc.

Articles

Immunoselective Targeting of an Anti-Thrombin Agent to the Surface of Cytokine-Activated Vascular Endothelial Cells

Jeanne-Marie Kiely; Myron I. Cybulsky; Francis W. Luscinskas; Michael A. Gimbrone, Jr

From the Vascular Research Division, Departments of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass.

Correspondence to Michael A. Gimbrone, Jr, MD, Vascular Research Division, Department of Pathology, Brigham and Women's Hospital, 221 Longwood Ave, LMRC-401, Boston, MA 02115-5817.

Abstract An immunoconjugate was designed to target hirudin, a potent and specific inhibitor of thrombin, to the surface of activated endothelial cells. Hirudin was covalently cross-linked to the monoclonal antibody H18/7 that recognizes the extracellular domain of E-selectin (CD62E), an endothelium-leukocyte adhesion molecule that is expressed only on cytokine-activated endothelium. The hirudin-H18/7 immunoconjugate selectively bound to interleukin-1–activated but not to unactivated cultured human umbilical vein endothelial cells with a temporal profile similar to that of inducible cell-surface procoagulant activity. When bound to activated endothelial cells, the hirudin-H18/7 immunoconjugate significantly inhibited endogenous thrombin activity generated from coincubated human plasma and fibrin clot formation on the monolayer surface. Cellular responses that are mediated via the thrombin receptor, such as increases in cytoskeletal F-actin content, also were significantly downregulated, and monolayers were protected from thrombin-induced disruption by this treatment. The ability to selectively antagonize thrombin-dependent processes at the endothelium-blood interface may provide new insights into complex pathophysiological processes, such as thrombosis, inflammation, and atherogenesis. These studies also demonstrate the general feasibility of selective targeting of therapeutic agents to endothelial cells based on recognition of an activation-dependent surface phenotype.

Key Words: immunotargeting • vascular endothelium • hirudin • E-selectin (CD62E) • thrombin

This article has been cited by other articles:

				B.-S. Ding, T. Dziubla, V. V. Shuvaev, S. Muro, and V. R. Muzykantov Advanced drug delivery systems that target the vascular endothelium. Mol. Interv., April 1, 2006; 6(2): 98 - 112. [Abstract] [Full Text] [PDF]

				B.-S. Ding, C. Gottstein, A. Grunow, A. Kuo, K. Ganguly, S. M. Albelda, D. B. Cines, and V. R. Muzykantov Endothelial targeting of a recombinant construct fusing a PECAM-1 single-chain variable antibody fragment (scFv) with prourokinase facilitates prophylactic thrombolysis in the pulmonary vasculature Blood, December 15, 2005; 106(13): 4191 - 4198. [Abstract] [Full Text] [PDF]

				D. Chen, K. Giannopoulos, P. G. Shiels, Z. Webster, J. H. McVey, G. Kemball-Cook, E. Tuddenham, M. Moore, R. Lechler, and A. Dorling Inhibition of intravascular thrombosis in murine endotoxemia by targeted expression of hirudin and tissue factor pathway inhibitor analogs to activated endothelium Blood, September 1, 2004; 104(5): 1344 - 1349. [Abstract] [Full Text] [PDF]

				M. Christofidou-Solomidou, A. Scherpereel, R. Wiewrodt, K. Ng, T. Sweitzer, E. Arguiri, V. Shuvaev, C. C. Solomides, S. M. Albelda, and V. R. Muzykantov PECAM-directed delivery of catalase to endothelium protects against pulmonary vascular oxidative stress Am J Physiol Lung Cell Mol Physiol, August 1, 2003; 285(2): L283 - L292. [Abstract] [Full Text] [PDF]

				M. Yoshida, T. Sawada, H. Ishii, R. E. Gerszten, A. Rosenzweig, M. A. Gimbrone Jr, Y. Yasukochi, and F. Numano HMG-CoA Reductase Inhibitor Modulates Monocyte-Endothelial Cell Interaction Under Physiological Flow Conditions In Vitro : Involvement of Rho GTPase-Dependent Mechanism Arterioscler. Thromb. Vasc. Biol., July 1, 2001; 21(7): 1165 - 1171. [Abstract] [Full Text] [PDF]

				K. Riesbeck, D. Chen, G. Kemball-Cook, J. H. McVey, A. J. T. George, E. G. D. Tuddenham, A. Dorling, and R. I. Lechler Expression of Hirudin Fusion Proteins in Mammalian Cells : A Strategy for Prevention of Intravascular Thrombosis Circulation, December 15, 1998; 98(24): 2744 - 2752. [Abstract] [Full Text] [PDF]

				D. D. Spragg, D. R. Alford, R. Greferath, C. E. Larsen, K.-D. Lee, G. C. Gurtner, M. I. Cybulsky, P. F. Tosi, C. Nicolau, and M. A. Gimbrone Jr. Immunotargeting of liposomes to activated vascular endothelial cells: A strategy for site-selective delivery in the cardiovascular system PNAS, August 5, 1997; 94(16): 8795 - 8800. [Abstract] [Full Text] [PDF]